Table 1.
Patient and disease characteristics
| AA cohort (N=81) |
Enzalutamide cohort (N=51) |
|||
|---|---|---|---|---|
| N | % | N | % | |
| At diagnosis of cancer | ||||
| Gleason | ||||
| 6 or less | 7 | 8.6 | 8 | 15.7 |
| 7 | 27 | 33.3 | 16 | 31.4 |
| 8-10 | 40 | 49.4 | 21 | 41.2 |
| Unknown | 7 | 8.6 | 6 | 11.8 |
| At treatment initiation | ||||
| ECOG performance status | ||||
| 0 | 62 | 76.5 | 28 | 54.9 |
| 1 | 9 | 11.1 | 16 | 31.4 |
| ≥2 | 5 | 6.2 | 5 | 9.8 |
| Unknown | 5 | 6.2 | 2 | 3.9 |
| Presence of metastasis | 79 | 97.5 | 50 | 98.0 |
| Low albumin(<LLN)* | 5 | 6.8 | 7 | 14.3 |
| Prior use of Docetaxel** | 25 | 30.9 | 23 | 45.1 |
| Prior use of AA** | - | - | 35 | 68.6 |
| Prior use of Enzalutamide** | 4 | 4.9 | - | - |
| Age, years (median) | 68.3 | IQR:62-74 Range:46-89 |
69.0 | IQR:63-74 Range:50-88 |
| PSA,ng/mL (median) | 16.4 | IQR:4.8-52.1 Range: 0.1-972.1 |
45.5 | IQR:7.4-126.6 Range: 0.3-1148.4 |
|
Months from sample collection
to treatment start |
||||
| ≤3 | 33 | 40.7 | 19 | 37.3 |
| 3~6 | 20 | 24.7 | 13 | 25.5 |
| >6 | 28 | 34.6 | 19 | 37.3 |
*
evaluable N=74 and 49 for AA and enzalutamide cohort, respectively
**
treatment for metastasis or as a secondary hormone for castration-resistant prostate